Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00054249 · ClinicalTrials.gov registry record · Phase 2
T900607 in Treating Patients With Gastroesophageal Junction Cancer
A Phase 2 study of Gastric Cancer, sponsored by University Hospitals Seidman Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 1
- Study location
NCT00054249 is a Phase 2 study of Gastric Cancer that has completed, run by University Hospitals Seidman Cancer Center. The trial reports 1 study location across 1 state.
The verdict
NCT00054249, a Phase 2 study of Gastric Cancer, has completed, sponsored by University Hospitals Seidman Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1
- Study location
Study Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of T900607 in treating patients who have gastroesophageal junction cancer.
Conditions Studied
Interventions
- DRUG T900607
Study Locations (1)
Ohio
- Ireland Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-09 |
| Est. Completion | 2010-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00054249
The ClinicalTrials.gov registry entry for NCT00054249 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is University Hospitals Seidman Cancer Center, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gastric Cancer appearing as the primary indexed condition, and to 1 intervention - of which T900607 is the first listed.
NCT00054249 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT00054249 about?
NCT00054249 is a clinical study titled "T900607 in Treating Patients With Gastroesophageal Junction Cancer". RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of T900607 in treating patients who have gastroesophageal junction cancer.
What is the current status of trial NCT00054249?
This trial is currently completed. It is a Phase 2 study. The study started on 2002-09. Estimated completion is 2010-09.
What conditions does trial NCT00054249 study?
This clinical trial studies the following conditions: Gastric Cancer.
What interventions are being tested in trial NCT00054249?
The interventions under investigation include: T900607 (DRUG).
Who is sponsoring clinical trial NCT00054249?
This trial is sponsored by University Hospitals Seidman Cancer Center, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00054249 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Combination of TATE and PD-1 Inhibitor in Liver Cancer
RECRUITING · Phase 2
-
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
RECRUITING · Phase 2
-
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.